1. Home
  2. IVVD
  3. IVVD News

Latest Invivyd Inc. (IVVD) News on September 14, 2025

Could Invivyd's (IVVD) Expanding Antibody Pipeline Redefine Its Long-Term Therapeutic Strategy?
IVVD

Simply Wall St.

8 days ago

Could Invivyd's (IVVD) Expanding Antibody Pipeline Redefine Its Long-Term Therapeutic Strategy?

IVVD

MT Newswires

23 days ago

Invivyd Closes $57.5 Million Public Offering

Invivyd Announces Closing of $57.5 Million Public Offering and Full Exercise of the Underwriter’s Option to Purchase Additional Shares
IVVD

GlobeNewswire

23 days ago

Invivyd Announces Closing of $57.5 Million Public Offering and Full Exercise of the Underwriter’s Option to Purchase Additional Shares

IVVD

MT Newswires

24 days ago

Update: Invivyd Shares Fall After Company Prices $50 Million Offering of Stock, Warrants

IVVD

MT Newswires

24 days ago

Exchange-Traded Funds, Equity Futures Lower Pre-Bell Thursday Ahead of Jackson Hole Economic Symposium

IVVD

MT Newswires

24 days ago

Invivyd Prices $50 Million Offering of Stock, Warrants

Invivyd Announces Pricing of $50 Million Public Offering of Common Stock and Pre-Funded Warrants
IVVD

GlobeNewswire

24 days ago

Invivyd Announces Pricing of $50 Million Public Offering of Common Stock and Pre-Funded Warrants

IVVD

MT Newswires

25 days ago

Invivyd Announces Public Stock Offering

Invivyd Announces Proposed Public Offering of Common Stock
IVVD

GlobeNewswire

25 days ago

Invivyd Announces Proposed Public Offering of Common Stock

IVVD

MT Newswires

3 months ago

Invivyd Says Study Shows VYD2311 Well Tolerated as COVID-19 Drug Candidate

Invivyd Announces Positive Full Phase 1/2 Clinical Data for VYD2311, a Next Generation COVID-19 Monoclonal Antibody for Potential Use as a Non-Vaccine Preventative and for Treatment of Active Infection
IVVD

GlobeNewswire

3 months ago

Invivyd Announces Positive Full Phase 1/2 Clinical Data for VYD2311, a Next Generation COVID-19 Monoclonal Antibody for Potential Use as a Non-Vaccine Preventative and for Treatment of Active Infection

COVID’s remaining biotech contenders navigate a dwindling market
IVVD

Pharma Voice

3 months ago

COVID’s remaining biotech contenders navigate a dwindling market

Ulta Stock Jumps as Beauty Product Spending Continues
IVVD

Investopedia

3 months ago

Ulta Stock Jumps as Beauty Product Spending Continues

Silicon Photonics Market Set to Surge to USD 13.9 Billion by 2034, Driven by 12.5% CAGR | Exactitude Consultancy
IVVD

GlobeNewswire

3 months ago

Silicon Photonics Market Set to Surge to USD 13.9 Billion by 2034, Driven by 12.5% CAGR | Exactitude Consultancy

Drone Light Show Market to Soar to $5 Billion by 2034, Fueled by 13% CAGR and Rising Demand for Innovative Entertainment | Exactitude Consultancy
IVVD

GlobeNewswire

3 months ago

Drone Light Show Market to Soar to $5 Billion by 2034, Fueled by 13% CAGR and Rising Demand for Innovative Entertainment | Exactitude Consultancy

Northrop Grumman Raises $1 Billion Via Debt
IVVD

Benzinga

3 months ago

Northrop Grumman Raises $1 Billion Via Debt

The York Water Company Files a Rate Request Based on $145 Million in Investment
IVVD

GlobeNewswire

3 months ago

The York Water Company Files a Rate Request Based on $145 Million in Investment

TEN, Ltd. Announces Date for the First Quarter 2025 Results, Conference Call and Webcast
IVVD

GlobeNewswire

3 months ago

TEN, Ltd. Announces Date for the First Quarter 2025 Results, Conference Call and Webcast

IVVD

Newsfile

3 months ago

Max Resource Corp. Announces Participation in THE Mining Investment Event, Quebec City, June 3-5, 2025

Spinosad Active Ingredient Market Set for Steady Growth, Driven by Sustainable Farming Trends | Exactitude Consultancy
IVVD

GlobeNewswire

3 months ago

Spinosad Active Ingredient Market Set for Steady Growth, Driven by Sustainable Farming Trends | Exactitude Consultancy

H.C. Wainwright Lowers Invivyd (IVVD) PT to $5 Amid Q1 2025 Revenue Shortfall
IVVD

Insider Monkey

4 months ago

H.C. Wainwright Lowers Invivyd (IVVD) PT to $5 Amid Q1 2025 Revenue Shortfall

Invivyd Announces Publication of Landmark CANOPY Phase 3 PEMGARDA® (pemivibart) Clinical Trial; Results Underscore Strong Efficacy of Monoclonal Antibodies in Preventing COVID-19 in a Modern U.S. Population Against Relevant, Immune-Evasive SARS-CoV-2 Virus
IVVD

GlobeNewswire

4 months ago

Invivyd Announces Publication of Landmark CANOPY Phase 3 PEMGARDA® (pemivibart) Clinical Trial; Results Underscore Strong Efficacy of Monoclonal Antibodies in Preventing COVID-19 in a Modern U.S. Population Against Relevant, Immune-Evasive SARS-CoV-2 Virus

IVVD

MT Newswires

4 months ago

Invivyd's Pemgarda Added to NCCN Guidelines in Oncology for B-Cell Lymphomas

Invivyd Announces Inclusion of PEMGARDA® (pemivibart) in National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for B-Cell Lymphomas
IVVD

GlobeNewswire

4 months ago

Invivyd Announces Inclusion of PEMGARDA® (pemivibart) in National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for B-Cell Lymphomas

Invivyd Commends FDA Focus on Contemporary Evidence In Evaluating Medical Interventions To Prevent COVID-19
IVVD

GlobeNewswire

4 months ago

Invivyd Commends FDA Focus on Contemporary Evidence In Evaluating Medical Interventions To Prevent COVID-19

IVVD

GuruFocus.com

4 months ago

Invivyd Inc (IVVD) Q1 2025 Earnings Call Highlights: Strategic Shifts and Financial Discipline ...

IVVD

Thomson Reuters StreetEvents

4 months ago

Q1 2025 Invivyd Inc Earnings Call

Invivyd, Inc. (IVVD) Reports Q1 Loss, Lags Revenue Estimates
IVVD

Zacks

4 months ago

Invivyd, Inc. (IVVD) Reports Q1 Loss, Lags Revenue Estimates

Invivyd Reports First Quarter 2025 Financial Results and Recent Business Highlights
IVVD

GlobeNewswire

4 months ago

Invivyd Reports First Quarter 2025 Financial Results and Recent Business Highlights

What To Expect From Invivyd Inc (IVVD) Q1 2025 Earnings
IVVD

GuruFocus.com

4 months ago

What To Expect From Invivyd Inc (IVVD) Q1 2025 Earnings

IVVD

MT Newswires

4 months ago

Invivyd Urges US FDA to Focus on Monoclonal Antibodies for COVID-19 Prevention, Re-Assess Vaccine Efficacy

Invivyd Files Citizen Petition Urging FDA to Focus on Monoclonal Antibodies For Endemic-Virus-Era COVID-19 Prevention, and to Re-Assess COVID-19 Vaccine Efficacy
IVVD

GlobeNewswire

4 months ago

Invivyd Files Citizen Petition Urging FDA to Focus on Monoclonal Antibodies For Endemic-Virus-Era COVID-19 Prevention, and to Re-Assess COVID-19 Vaccine Efficacy

Invivyd to Participate at the H.C. Wainwright 3rd Annual BioConnect Investor Conference
IVVD

GlobeNewswire

4 months ago

Invivyd to Participate at the H.C. Wainwright 3rd Annual BioConnect Investor Conference

Invivyd to Host First Quarter 2025 Financial Results and Corporate Update Conference Call on May 15, 2025
IVVD

GlobeNewswire

4 months ago

Invivyd to Host First Quarter 2025 Financial Results and Corporate Update Conference Call on May 15, 2025

What's Going On With Invivyd Stock On Monday?
IVVD

Benzinga

5 months ago

What's Going On With Invivyd Stock On Monday?

Invivyd Announces $30M Non-dilutive Loan Facility with Silicon Valley Bank
IVVD

GlobeNewswire

5 months ago

Invivyd Announces $30M Non-dilutive Loan Facility with Silicon Valley Bank

Invivyd Appoints Ajay Royan, Founder of Mithril Capital, to its Board of Directors
IVVD

GlobeNewswire

6 months ago

Invivyd Appoints Ajay Royan, Founder of Mithril Capital, to its Board of Directors

Invivyd, Inc. (IVVD) Reports Q4 Loss, Tops Revenue Estimates
IVVD

Zacks

6 months ago

Invivyd, Inc. (IVVD) Reports Q4 Loss, Tops Revenue Estimates

Invivyd Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Recent Business Highlights
IVVD

GlobeNewswire

6 months ago

Invivyd Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Recent Business Highlights

Are Investors Undervaluing Invivyd, Inc. (IVVD) Right Now?
IVVD

Zacks

6 months ago

Are Investors Undervaluing Invivyd, Inc. (IVVD) Right Now?

Invivyd Announces Continued Neutralizing Activity of PEMGARDA™ (pemivibart) Against Currently Dominant SARS-CoV-2 Variant LP.8.1
IVVD

GlobeNewswire

6 months ago

Invivyd Announces Continued Neutralizing Activity of PEMGARDA™ (pemivibart) Against Currently Dominant SARS-CoV-2 Variant LP.8.1

Invivyd (NasdaqGM:IVVD) Jumps 163% After Promising Phase 1/2 Trial Results For COVID-19 Antibody
IVVD

Simply Wall St.

6 months ago

Invivyd (NasdaqGM:IVVD) Jumps 163% After Promising Phase 1/2 Trial Results For COVID-19 Antibody

Why Invivyd, Inc. (IVVD) is Skyrocketing So Far in 2025
IVVD

Insider Monkey

6 months ago

Why Invivyd, Inc. (IVVD) is Skyrocketing So Far in 2025

Adagio Medical cuts workforce and pauses cryo catheter launch in EU
IVVD

Medical Device Network

7 months ago

Adagio Medical cuts workforce and pauses cryo catheter launch in EU

The Zacks Analyst Blog Highlights INVIVYD, 21Vianet, FuboTV, Noodles and Digital Turbine
IVVD

Zacks

7 months ago

The Zacks Analyst Blog Highlights INVIVYD, 21Vianet, FuboTV, Noodles and Digital Turbine

IVVD

MT Newswires

7 months ago

Sector Update: Health Care Stocks Gain Monday Afternoon

5 Stocks That More Than Doubled Halfway Through Q1
IVVD

Zacks

7 months ago

5 Stocks That More Than Doubled Halfway Through Q1

IVVD

MT Newswires

7 months ago

Sector Update: Health Care Stocks Flat to Higher Pre-Bell Monday

IVVD

MT Newswires

7 months ago

Sector Update: Health Care

IVVD

MT Newswires

7 months ago

Invivyd's Request to Treat Covid-19 Patients With Pemgarda Rejected by US FDA

FDA Declined Invivyd’s Request to Expand Existing Emergency Use Authorization of PEMGARDA™ (pemivibart) to Include Treatment of Mild-to-Moderate COVID-19 For Immunocompromised Persons Who Have No Alternative Therapeutic Options; No Change to the Existing PEMGARDA EUA for Pre-Exposure Prophylaxis of COVID-19 in Certain Immunocompromised Patients
IVVD

GlobeNewswire

7 months ago

FDA Declined Invivyd’s Request to Expand Existing Emergency Use Authorization of PEMGARDA™ (pemivibart) to Include Treatment of Mild-to-Moderate COVID-19 For Immunocompromised Persons Who Have No Alternative Therapeutic Options; No Change to the Existing PEMGARDA EUA for Pre-Exposure Prophylaxis of COVID-19 in Certain Immunocompromised Patients

Why Invivyd, Inc. (IVVD) Is Soaring This Year So Far
IVVD

Insider Monkey

7 months ago

Why Invivyd, Inc. (IVVD) Is Soaring This Year So Far

Invivyd to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 12, 2025
IVVD

GlobeNewswire

7 months ago

Invivyd to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 12, 2025

Exploring High Growth Tech Stocks in the United States
IVVD

Simply Wall St.

7 months ago

Exploring High Growth Tech Stocks in the United States

Invivyd Announces Partnership with Pro Football Coach Jim Harbaugh to Elevate Awareness and Ongoing Impact of COVID-19: Common, Not A Cold
IVVD

GlobeNewswire

7 months ago

Invivyd Announces Partnership with Pro Football Coach Jim Harbaugh to Elevate Awareness and Ongoing Impact of COVID-19: Common, Not A Cold

IVVD

MT Newswires

7 months ago

Invivyd Shares Soar Premarket After Tripling Monday Following Initial Results From COVID-19 Vaccination Alternative

Why Invivyd Inc (IVVD) Is Skyrocketing So Far In 2025
IVVD

Insider Monkey

7 months ago

Why Invivyd Inc (IVVD) Is Skyrocketing So Far In 2025

Invivyd Announces Positive Phase 1/2 Clinical Data for VYD2311, a Monoclonal Antibody Designed to be a Superior Alternative to COVID-19 Vaccination for the Broad Population
IVVD

GlobeNewswire

7 months ago

Invivyd Announces Positive Phase 1/2 Clinical Data for VYD2311, a Monoclonal Antibody Designed to be a Superior Alternative to COVID-19 Vaccination for the Broad Population

Invivyd Announces Preliminary Fourth Quarter 2024 Financial Results, Strong Revenue Growth, and Reiterates Goal of Near-Term Profitability
IVVD

GlobeNewswire

7 months ago

Invivyd Announces Preliminary Fourth Quarter 2024 Financial Results, Strong Revenue Growth, and Reiterates Goal of Near-Term Profitability

We Might See A Profit From Invivyd, Inc. (NASDAQ:IVVD) Soon
IVVD

Simply Wall St.

7 months ago

We Might See A Profit From Invivyd, Inc. (NASDAQ:IVVD) Soon

Invivyd Provides Another Positive SARS-CoV-2 Variant Data Analysis to Satisfy U.S. FDA’s Gating Request for Completing Its Review of EUA Request for PEMGARDA™ (pemivibart) for the Treatment of Mild-to-Moderate COVID-19 in Certain Immunocompromised Patients
IVVD

GlobeNewswire

8 months ago

Invivyd Provides Another Positive SARS-CoV-2 Variant Data Analysis to Satisfy U.S. FDA’s Gating Request for Completing Its Review of EUA Request for PEMGARDA™ (pemivibart) for the Treatment of Mild-to-Moderate COVID-19 in Certain Immunocompromised Patients

What's Going On With COVID-19 Antibody Developer Invivyd Stock On Friday?
IVVD

Benzinga

8 months ago

What's Going On With COVID-19 Antibody Developer Invivyd Stock On Friday?

Invivyd Announces Continued Neutralizing Activity of PEMGARDA™ (pemivibart) Against Dominant SARS-CoV-2 Variant XEC
IVVD

GlobeNewswire

8 months ago

Invivyd Announces Continued Neutralizing Activity of PEMGARDA™ (pemivibart) Against Dominant SARS-CoV-2 Variant XEC

Why Invivyd, Inc. (IVVD) Is Among the Best Penny Stocks to Invest In According to Media?
IVVD

Insider Monkey

8 months ago

Why Invivyd, Inc. (IVVD) Is Among the Best Penny Stocks to Invest In According to Media?

Adagio Medical announces Todd Usen as new CEO and director
IVVD

Medical Device Network

9 months ago

Adagio Medical announces Todd Usen as new CEO and director

IVVD

MT Newswires

9 months ago

Adagio Medical Appoints Todd Usen as CEO

IVVD

Thomson Reuters StreetEvents

10 months ago

Q3 2024 Invivyd Inc Earnings Call

IVVD

GuruFocus.com

10 months ago

Invivyd Inc (IVVD) Q3 2024 Earnings Call Highlights: Strong Revenue and Strategic Growth Amidst ...

Invivyd, Inc. (IVVD) Reports Q3 Loss, Misses Revenue Estimates
IVVD

Zacks

10 months ago

Invivyd, Inc. (IVVD) Reports Q3 Loss, Misses Revenue Estimates

Invivyd Reports Third Quarter 2024 Financial Results and Recent Business Highlights
IVVD

GlobeNewswire

10 months ago

Invivyd Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Invivyd Announces New England Journal of Medicine Publishes Letter to the Editor Highlighting Immunobridging Pathway Leading to PEMGARDA™ (pemivibart) Emergency Use Authorization; Comments on Adjacent Third-Party Letter to the Editor
IVVD

GlobeNewswire

10 months ago

Invivyd Announces New England Journal of Medicine Publishes Letter to the Editor Highlighting Immunobridging Pathway Leading to PEMGARDA™ (pemivibart) Emergency Use Authorization; Comments on Adjacent Third-Party Letter to the Editor

Invivyd Inc (IVVD) Q3 2024 Earnings Report Preview: What to Expect
IVVD

GuruFocus.com

10 months ago

Invivyd Inc (IVVD) Q3 2024 Earnings Report Preview: What to Expect

Invivyd Announces Preprints Conveying CANOPY Phase 3 Clinical Trial Data Including Long-Term Protection Versus Recent JN.1 Sublineages at Low Residual Titers, and Describing a Novel Approach for Predicting Monoclonal Antibody Activity Were Uploaded to MedRxiv and BioRxiv, Respectively
IVVD

GlobeNewswire

10 months ago

Invivyd Announces Preprints Conveying CANOPY Phase 3 Clinical Trial Data Including Long-Term Protection Versus Recent JN.1 Sublineages at Low Residual Titers, and Describing a Novel Approach for Predicting Monoclonal Antibody Activity Were Uploaded to MedRxiv and BioRxiv, Respectively

Invivyd to Participate in the Guggenheim Securities Healthcare Innovation Conference
IVVD

GlobeNewswire

10 months ago

Invivyd to Participate in the Guggenheim Securities Healthcare Innovation Conference

Invivyd to Host Third Quarter 2024 Financial Results and Corporate Update Conference Call on November 14, 2024
IVVD

GlobeNewswire

10 months ago

Invivyd to Host Third Quarter 2024 Financial Results and Corporate Update Conference Call on November 14, 2024

IVVD

MT Newswires

a year ago

Invivyd Shares Fall After Revenue Guidance Withdrawal

Invivyd Reports Preliminary Third Quarter 2024 Results, Withdraws Prior Financial Guidance, and Targets Near-Term Profitability
IVVD

GlobeNewswire

a year ago

Invivyd Reports Preliminary Third Quarter 2024 Results, Withdraws Prior Financial Guidance, and Targets Near-Term Profitability

Invivyd Phase 3 Long-Term Exploratory Clinical Efficacy Data Shows PEMGARDA™ (pemivibart) Provided Substantial Protection from Symptomatic COVID-19 Versus Placebo Over Six Months of Follow-Up, With No Additional Doses, In Immunocompetent Participants
IVVD

GlobeNewswire

a year ago

Invivyd Phase 3 Long-Term Exploratory Clinical Efficacy Data Shows PEMGARDA™ (pemivibart) Provided Substantial Protection from Symptomatic COVID-19 Versus Placebo Over Six Months of Follow-Up, With No Additional Doses, In Immunocompetent Participants

Invivyd to Present PEMGARDA™ (pemivibart) Data at Infectious Disease Week (IDWeek) 2024
IVVD

GlobeNewswire

a year ago

Invivyd to Present PEMGARDA™ (pemivibart) Data at Infectious Disease Week (IDWeek) 2024

Invivyd Announces U.S. FDA Has Updated the PEMGARDA™ EUA Fact Sheet with Accurate SARS-CoV-2 Variant Susceptibility and PEMGARDA Activity Data
IVVD

GlobeNewswire

a year ago

Invivyd Announces U.S. FDA Has Updated the PEMGARDA™ EUA Fact Sheet with Accurate SARS-CoV-2 Variant Susceptibility and PEMGARDA Activity Data

IVVD

MT Newswires

a year ago

Invivyd Provides Virology Data Supporting Pemivibart's Effectiveness Against Current SARS-CoV-2 Variants

Invivyd Provides Detailed Virology Data and Analysis of SARS-CoV-2 Structural Biology Predicting Anticipated Neutralization Activity for PEMGARDA™ (pemivibart)
IVVD

GlobeNewswire

a year ago

Invivyd Provides Detailed Virology Data and Analysis of SARS-CoV-2 Structural Biology Predicting Anticipated Neutralization Activity for PEMGARDA™ (pemivibart)

We're Keeping An Eye On Invivyd's (NASDAQ:IVVD) Cash Burn Rate
IVVD

Simply Wall St.

a year ago

We're Keeping An Eye On Invivyd's (NASDAQ:IVVD) Cash Burn Rate

Invivyd at the Ready for Upcoming Respiratory Virus Season with PEMGARDA™ (pemivibart) to Help Protect Vulnerable Immunocompromised Persons from COVID-19
IVVD

GlobeNewswire

a year ago

Invivyd at the Ready for Upcoming Respiratory Virus Season with PEMGARDA™ (pemivibart) to Help Protect Vulnerable Immunocompromised Persons from COVID-19

Invivyd to Participate in Upcoming Investor Conferences
IVVD

GlobeNewswire

a year ago

Invivyd to Participate in Upcoming Investor Conferences

Invivyd Doses First Participants in Phase 1 Clinical Trial of VYD2311, a Next Generation Monoclonal Antibody Candidate for COVID-19, Building on the Success of PEMGARDA™
IVVD

GlobeNewswire

a year ago

Invivyd Doses First Participants in Phase 1 Clinical Trial of VYD2311, a Next Generation Monoclonal Antibody Candidate for COVID-19, Building on the Success of PEMGARDA™

Invivyd Announces Continued Neutralizing Activity of PEMGARDA™ (pemivibart) Against Dominant SARS-CoV-2 Variants KP.3.1.1 and LB.1, and Other Variants of Interest
IVVD

GlobeNewswire

a year ago

Invivyd Announces Continued Neutralizing Activity of PEMGARDA™ (pemivibart) Against Dominant SARS-CoV-2 Variants KP.3.1.1 and LB.1, and Other Variants of Interest

IVVD

MT Newswires

a year ago

Invivyd's Covid-19 Antibody Shows 84% Risk Reduction in Phase 3 Trial; Shares Fall

Invivyd Announces PEMGARDA™ (pemivibart) Demonstrated 84% Relative Risk Reduction in Symptomatic COVID-19 Compared to Placebo in an Exploratory Analysis from Ongoing CANOPY Phase 3 Clinical Trial
IVVD

GlobeNewswire

a year ago

Invivyd Announces PEMGARDA™ (pemivibart) Demonstrated 84% Relative Risk Reduction in Symptomatic COVID-19 Compared to Placebo in an Exploratory Analysis from Ongoing CANOPY Phase 3 Clinical Trial

IVVD

Thomson Reuters StreetEvents

a year ago

Q2 2024 Invivyd Inc Earnings Call

Invivyd, Inc. (IVVD) Reports Q2 Loss, Lags Revenue Estimates
IVVD

Zacks

a year ago

Invivyd, Inc. (IVVD) Reports Q2 Loss, Lags Revenue Estimates

Invivyd Reports Second Quarter 2024 Financial Results and Recent Business Highlights
IVVD

GlobeNewswire

a year ago

Invivyd Reports Second Quarter 2024 Financial Results and Recent Business Highlights

Invivyd to Host Conference Call Discussing Second Quarter 2024 Financial Results and Business Highlights
IVVD

GlobeNewswire

a year ago

Invivyd to Host Conference Call Discussing Second Quarter 2024 Financial Results and Business Highlights

IVVD

MT Newswires

a year ago

Invivyd Joining Russell 2000, 3000 Indexes

Invivyd Announces its Addition to the Russell 2000® and Russell 3000® Indexes
IVVD

GlobeNewswire

a year ago

Invivyd Announces its Addition to the Russell 2000® and Russell 3000® Indexes

Invivyd, Inc. (NASDAQ:IVVD) Is Expected To Breakeven In The Near Future
IVVD

Simply Wall St.

a year ago

Invivyd, Inc. (NASDAQ:IVVD) Is Expected To Breakeven In The Near Future

Invivyd Announces Antiviral Activity of VYD222 (pemivibart) Against SARS-CoV-2 KP.1.1 FLiRT & KP.3 Variants
IVVD

GlobeNewswire

a year ago

Invivyd Announces Antiviral Activity of VYD222 (pemivibart) Against SARS-CoV-2 KP.1.1 FLiRT & KP.3 Variants

Invivyd to Participate at the Jefferies Global Healthcare Conference
IVVD

GlobeNewswire

a year ago

Invivyd to Participate at the Jefferies Global Healthcare Conference

IVVD

MT Newswires

a year ago

Invivyd in General Alignment With FDA on Emergency Use Authorization Pathway for Monoclonal Covid Antibodies

Invivyd Announces General Alignment with U.S. FDA on a Repeatable, Expedient Emergency Use Authorization Pathway for the Prevention and Treatment of Symptomatic COVID-19, Based on Compact Clinical Programs to Establish Safety and Immunobridging for Serial Monoclonal Antibodies
IVVD

GlobeNewswire

a year ago

Invivyd Announces General Alignment with U.S. FDA on a Repeatable, Expedient Emergency Use Authorization Pathway for the Prevention and Treatment of Symptomatic COVID-19, Based on Compact Clinical Programs to Establish Safety and Immunobridging for Serial Monoclonal Antibodies

Share on Social Networks: